BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials

BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials

BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world's first dual-payload antibody –drug conjugate (ADC) to enter clinical development. BioDlink enabled IND...

AITO and ADM Enter into Strategic Partnership, Marking a New Chapter in the Global Expansion of Intelligent Luxury

AITO and ADM Enter into Strategic Partnership, Marking a New Chapter in the Global Expansion of Intelligent Luxury

CHONGQING, China, Feb. 6, 2026 /PRNewswire/ -- AITO, China's luxury intelligent vehicle brand, has officially signed a strategic cooperation agreement with Performance Plus Motors (subsidiary of Abu Dhabi Motors), a leading luxury automotive dealer...

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an...

Dingdong Announces Entry into Definitive Agreement to Sell its China Business to Meituan

Dingdong Announces Entry into Definitive Agreement to Sell its China Business to Meituan

SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Dingdong (Cayman) Limited ("Dingdong" or the "Company") (NYSE: DDL), a leading fresh grocery e-commerce company in China, today announced that it has entered into a definitive Share Purchase Agreement (the...

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

SHANGHAI, Jan. 29, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development...

"Yiwu Right Away" Promotional Video Released, 2026 Spring Festival Gala Preparations in Yiwu Enter Final Stage

"Yiwu Right Away" Promotional Video Released, 2026 Spring Festival Gala Preparations in Yiwu Enter Final Stage

YIWU, China, Jan. 26, 2026 /PRNewswire/ -- A news report from Yiwu Media Convergence Center: Today marks the traditional Chinese Laba Festival, heralding the approach of the Lunar Chinese New Year. A promotional video titled "Yiwu Right Away" for...

HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics...

Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment

Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment

Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both...

SF Holding and J&T Express Enter Subscription Agreement to Advance International Strategy and Enhance Global Logistics Presence

SF Holding and J&T Express Enter Subscription Agreement to Advance International Strategy and Enhance Global Logistics Presence

HONG KONG, Jan. 15, 2026 /PRNewswire/ -- S.F. Holding Co., Ltd. ('SF Holding' or 'SF', 'the Company', 002352.SZ; 06936.HK) the largest integrated logistics service provider in Asia and the fourth largest globally, and J&T Global Express...

Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates

Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates

-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX:...

  • 1
  • 2
  • menu
    menu